Immunome, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMNM research report →
Range $24 – $37
Price Chart
About the company
Immunome, Inc. , a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
- CEO
- Clay Siegall
- IPO
- 2020
- Employees
- 247
- HQ
- Bothell, WA, US
Get TickerSpark's AI analysis on IMNM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.90B
- P/E
- -7.81
- Fwd P/E
- 36.34
- PEG
- -0.47
- P/S
- 0.00
- P/B
- 4.28
- EV/EBITDA
- -6.70
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -50.56%
- ROIC
- -51.06%
Latest fiscal year · YoY change
- Revenue
- $6.94M-23.2%
- Gross Profit
- $3.99M-55.9%
- Op Income
- $-214,113,000
- Net Income
- $-212,394,000+27.5%
- EPS
- $-2.43+51.4%
- OCF Growth
- -72.3%
- FCF Growth
- -22.1%
- 52W High
- $30.06
- 52W Low
- $13.41
- 50D MA
- $25.23
- 200D MA
- $22.75
- Beta
- 2.13
- RSI (14)
- 29
- Avg Volume
- 1.19M
No earnings-call transcripts are available for IMNM yet.
- Free Float
- 82.9%
- Shares Outstanding
- 95.60M
- Float Shares
- 79.25M
of shares held by institutions
211 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19.68M | ▲ 3.31M |
| Fmr LLC | 16.99M | ▲ 17.60K |
| Blackrock, Inc. | 8.81M | ▲ 636.82K |
| Vanguard Group Inc | 6.04M | ▲ 1.14M |
| State Street Corp | 5.49M | ▲ 94.72K |
| Wellington Management Group Llp | 5.21M | ▲ 478.24K |
| Redmile Group, LLC | 4.91M | ▼ 647.29K |
| Primecap Management Co | 4.58M | ▼ 206.80K |
| Vanguard Capital Management LLC | 4.55M | ▲ 121.59K |
| Driehaus Capital Management LLC | 4.35M | ▲ 246.24K |
| Enavate Sciences Gp, LLC | 3.61M | 0 |
| Geode Capital Management, LLC | 2.75M | ▲ 194.22K |
Held by 289 ETFs
Biggest fund positions in IMNM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 11, 26 | Higgins Jack | other | 18,000 |
| Sep 11, 26 | Higgins Jack | other | 18,000 |
| Sep 11, 26 | Higgins Jack | sell | 13,200 |
| Sep 11, 26 | Higgins Jack | other | 8,800 |
| Aug 12, 26 | Barchas Isaac | sell | 11,048 |
| Aug 10, 26 | Barchas Isaac | sell | 10,125 |
| Aug 11, 26 | Barchas Isaac | sell | 62,291 |
| Aug 6, 26 | Barchas Isaac | sell | 20,840 |
| Aug 7, 26 | Barchas Isaac | sell | 15,248 |
| Aug 4, 26 | Horn Kinney | other | 40,250 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMNM coverage
Recent articles, reports, and earnings notes.
No research on IMNM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMNM report →Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
businesswire.com · Sep 30
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Sep 8
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
businesswire.com · Sep 2
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
marketbeat.com · Aug 17
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
globenewswire.com · Aug 17
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
seekingalpha.com · Aug 13
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
businesswire.com · Aug 11
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Aug 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.